Satoru Nihei1, Junya Sato2, Toshiyuki Harada3, Shoichi Kuyama4, Toshiro Suzuki5, Nobutsugu Waga6, Yoshitaka Saito7, Shigeki Kisara8, Atsuko Yokota9, Kouji Okada10, Masami Tsuchiya11, Kazufumi Terui12, Yumiko Tadokoro13, Takeshi Chiba1, Kenzo Kudo1, Satoshi Oizumi14, Akira Inoue15, Naoto Morikawa16. 1. Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, Iwate Medical University, School of Pharmacy, 2-1-1, Nishitokuta, Yahaba-cho, Shiwa-gun, 028-3694, Japan. 2. Department of Pharmacy, Shizuoka Cancer Center, 1007 Shimon agakubo, Nagaizumi-cho, Sunto-gun, 411-8777, Shizuoka Prefecture, Japan. 3. Center for Respiratory Disease, Japan Community Health Care Organization Hokkaido Hospital, 1-8-3-18, Nakanoshima, Toyohira-ku, Sapporo, 062-8618, Japan. 4. Department of Respiratory Medicine, National Hospital Organization Iwakuni Medical Center, 1-1-1, Atago-machi, Iwakuni, 740-8510, Japan. 5. Department of Internal Medicine, Iwate Prefectural Isawa Hospital, 61, Ryugababa, Mizusawa-ku, Oshu, 023-0864, Japan. 6. Department of Pharmacy, Iwate Prefectural Isawa Hospital, 61, Ryugababa, Mizusawa-ku, Oshu, 023-0864, Japan. 7. Department of Pharmacy, Hokkaido University Hospital, North 14, West 5, Kita-ku, Sapporo, 060-8648, Japan. 8. Department of Pharmacy, Tohoku University Hospital, 1-1, Seiryo-cho, Aoba-ku, Sendai, 980-8574, Japan. 9. Department of Pharmacy, Fukushima Medical University Hospital, 1, Hikarigaoka, Fukushima, 960-1247, Japan. 10. Department of Clinical Pharmaceutics and Pharmacy Practice, Tohoku Medical and Pharmaceutical University, 1-12-1, Fukumuro, Miyagino, Sendai, Miyagi, 983-8512, Japan. 11. Department of Pharmacy, Miyagi Cancer Center, 47-1, Nodayama, Medeshima-Shiote, Natori, 981-1293, Japan. 12. Department of Pharmacy, Hirosaki University Hospital, 53, Hon-cho, Hirosaki, Hirosaki, 036-8563, Japan. 13. Department of Pharmacy, Saka General Hospital, 16-5, Nishiki-cho, Shiogama, 985-8506, Japan. 14. Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer, 3-54 Kikusui 4-2 Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan. 15. Department of Palliative Medicine, Tohoku University School of Medicine, 2-1, Seiryo-cho, Aoba-ku, Sendai, 980-8575, Japan. 16. Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine, 19-1, Uchimaru, Morioka, Iwate, 020-8505, Japan. carcinoma@nifty.com.
Abstract
PURPOSE: The objective of this study was to investigate the effect of renin-angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We retrospectively reviewed the medical records of NSCLC patients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups. The primary outcome was a proteinuria event of any grade during the first 6 cycles of BV treatment. RESULTS: A total of 211 patients were included, 89 of whom received antihypertensive drugs. Of these 89 patients, 49 were in the RASI user group, and 40 were in the non-RASI user group. The non-user group comprised 122 patients. The occurrence of proteinuria in the RASI user group was significantly lower than that in the non-RASI user group (P = 0.037) but was not significantly lower than that in the non-user group (P = 0.287). Patients using RASIs had a lower rate of proteinuria than those who did not use RASIs according to multivariate analysis (odds ratio 0.32; 95% confidence interval 0.12-0.86; P = 0.024). CONCLUSION: Our study suggests that RASI administration reduces the risk of proteinuria in patients receiving BV.
PURPOSE: The objective of this study was to investigate the effect of renin-angiotensin system inhibitors (RASIs) on bevacizumab (BV)-induced proteinuria in non-small cell lung cancer (NSCLC) patients. MATERIALS AND METHODS: We retrospectively reviewed the medical records of NSCLCpatients receiving BV between 2008 and 2014 at 11 hospitals. The patients were categorized into three groups according to their antihypertensive drug use: RASI user, non-RASI user, and non-user groups. The primary outcome was a proteinuria event of any grade during the first 6 cycles of BV treatment. RESULTS: A total of 211 patients were included, 89 of whom received antihypertensive drugs. Of these 89 patients, 49 were in the RASI user group, and 40 were in the non-RASI user group. The non-user group comprised 122 patients. The occurrence of proteinuria in the RASI user group was significantly lower than that in the non-RASI user group (P = 0.037) but was not significantly lower than that in the non-user group (P = 0.287). Patients using RASIs had a lower rate of proteinuria than those who did not use RASIs according to multivariate analysis (odds ratio 0.32; 95% confidence interval 0.12-0.86; P = 0.024). CONCLUSION: Our study suggests that RASI administration reduces the risk of proteinuria in patients receiving BV.
Entities:
Keywords:
Bevacizumab; Non-small cell lung cancer; Proteinuria; Renin–angiotensin system inhibitor